Importantly, we found that treatment with MEK inhibitors significantly improves the lymphedema phenotype and restores valve formation in ephb4b−/− or rasa1a(-3)−/−;rasa1b−/− mutant larvae, providing a potential treatment strategy for valve-deficient disorders that currently lack specific molecular treatments. This evidence concerns the gene MAP2K7 and lymphedema.